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Abstract
Background: Though obesity is a well-known risk factor 
for vascular disease, the impact of obesity on stroke out-
come has been disputed. Several studies have shown that 
obesity is associated with better functional outcome after 
stroke. Whether obesity influences the benefit of endovascu-
lar treatment (EVT) in stroke patients is unknown. We evalu-
ated the association between body mass index (BMI) and 
outcome in acute ischemic stroke patients with large vessel 
 occlusion (LVO), and assessed whether BMI affects the 
 benefit of EVT. Methods: This is a post hoc analysis of the 
Multicenter Randomized Clinical Trial of Endovascular Treat-
ment for Acute Ischemic Stroke in the Netherlands trial 
( ISRCTN10888758). BMI was used as a continuous and cate-
gorical variable, distinguishing underweight and normal 
weight (BMI < 25), overweight (BMI 25–30), and obesity (BMI 
≥30). We used multivariable ordinal logistic regression analy-
sis to estimate the association of BMI with functional out-
come (shift analysis), assessed with modified Rankin Scale 
(mRs) at 90 days. The impact of BMI on EVT effect was tested 
by the use of a multiplicative interaction term. Results: Of 
366 patients, 160 (44%) were underweight or normal weight, 
145 (40%) overweight, and 61 (17%) were obese. In multivari-
able analysis with BMI as a continuous variable, we found a 
shift toward better functional outcome with higher BMI (mRS 
adjusted common OR  1.04; 95% CI 1.0–1.09), and mortality 
was inversely related to BMI (aOR 0.92; 95% CI 0.85–0.99). 
Safety analysis showed that higher BMI was associated with 
lower risk of stroke progression (aOR 0.92, 95% CI 0.87–0.99). 
Additional analysis showed no interaction between BMI and 
EVT effect on functional outcome, mortality, and other safety 
outcomes. Conclusion: Our study confirms the effect of obe-
sity on outcome in acute ischemic stroke patients with LVO, 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Obesity Paradox in Acute Ischemic Stroke 
Patients
201Cerebrovasc Dis 2019;48:200–206
DOI: 10.1159/000504744
meaning better functional outcome, lower mortality, and 
lower risk of stroke progression for patients with higher BMI. 
As we found no interaction between BMI and EVT effect, all 
BMI classes may expect the same benefit from EVT.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Obesity and overweight are well-known cardiovascu-
lar risk factors and associated with an increased risk of 
stroke. Each unit increase of body mass index (BMI) is 
independently associated with 6% increase in the relative 
risk of stroke [1]. However, the impact of obesity on func-
tional outcome after stroke remains controversial. Sev-
eral studies have reported that obesity is independently 
associated with a lower mortality rate after stroke [2, 3], 
while other studies could not confirm this [4, 5]. 
By comparison, a better outcome for obese patients 
has been described in a variety of acute and chronic vas-
cular diseases. As such, lower mortality rates and better 
recovery have been found in obese patients with heart 
failure, myocardial infarction, and chronic kidney disease 
[6, 7]. This contradiction, in which obesity increases the 
chance of a vascular disease, yet also contributes to better 
recovery afterward, is known as the obesity paradox. Its 
underlying mechanism is yet to be explained, and there-
fore remains a matter of ongoing debate.
Data on the impact of obesity on stroke treatment out-
comes are scarce. Most observational studies on function-
al outcome after intravenous thrombolysis for stroke in 
obese patients do not suggest an obesity paradox [8–10]. 
However, the obesity paradox has been confirmed in the 
outcome after carotid endarterectomy [11]. The impact 
of excess body weight on functional outcome and mortal-
ity after endovascular treatment (EVT) for acute stroke 
has not yet been reported. 
Now that the use of EVT for large vessel occlusions 
(LVO) is growing and the proportion of obese patients is 
increasing, we feel that exploration of the obesity paradox 
in this specific population is relevant. We hypothesize 
that increased BMI may be associated with a better out-
come in EVT-treated stroke patients. In this Multicenter 
Randomized Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the Netherlands (MR 
CLEAN) post hoc analysis, we (1) investigate the relation 
between BMI at hospital admission and functional out-
come and mortality in stroke patients and (2) assess 
whether BMI affects the benefit and safety of EVT in 
acute stroke patients. 
Methods
Study Design and Patients 
In this post hoc analysis, we used data from the MR CLEAN 
trial [12]. The study methods and patient eligibility criteria have 
been reported previously [13]. Source data will not be made 
available because of regulatory issues on patient privacy, but de-
tailed analytic methods and study materials, including log files 
of statistical analyses, will be made available to other researchers 
on request to the first author. MR CLEAN is a randomized, open 
label clinical trial of EVT versus no EVT along with usual care 
in patients from 16 centers in the Netherlands from 2010 until 
2014. All patients were intended to be treated for a proximal ar-
terial occlusion in the anterior circulation, within 6 h of symp-
tom onset. In total, 500 patients were included in the trial, with 
233 assigned to the intervention arm and 267 assigned to the 
control arm. The usual medical care management was per-
formed according to national guidelines, and could include 
treatment with intravenous thrombolysis within the first 4.5 h 
after symptom onset. 
All patients or their legal representative provided written in-
formed consent before randomization. The study protocol was ap-
proved by a central medical Ethics Committee and the research 
board of each participating center.
Body Mass Index
Risk factors as well as weight and height were recorded as base-
line parameters. Body weight was measured by nurses of the Emer-
gency department or Stroke Unit or obtained verbally from the 
patient or their caregiver. If neither was possible, body weight and 
height were estimated by the nurse or anesthetic team. We calcu-
lated BMI as the ratio of body weight and squared height, given as 
kg/m2. The patients were categorized as defined by the World 
Health Organization as underweight (BMI < 18.5 kg/m2), normal 
weight (BMI 18.5 to < 25 kg/m2), overweight (BMI 25 to < 30 kg/
m2), obesity (BMI 30 to < 35 kg/m2), and morbid obesity (BMI ≥35 
kg/m2). 
Outcome and Safety Measures
The primary outcome measure was the modified Ranking Scale 
(mRS) at 90 days, which is a 7-point scale ranging from 0 (no 
symptoms) to 6 (death) [14]. An mRS score of 6 means a patient 
has died during the 90 days of follow-up. A score of 2 points or less 
indicates functional independence. Secondary clinical outcome 
measures included neurological assessment with the National In-
stitute of Health Stroke Scale (NIHSS) at 24 h [15] and mortality 
rate by 90 days (mRS score 6 at 90 days). Secondary radiologic out-
come measures included arterial recanalization on CTA or mag-
netic resonance angiogram at 24 h, and final infarct volume on 
non-contrast CT at 5–7 days. All neuroimaging studies were eval-
uated by 2 neuroradiologists who were blinded for the treatment-
group assignments. 
We also tested safety parameters, which included hemorrhagic 
complications, progression of ischemic stroke, and pneumonia. 
Symptomatic intracranial hemorrhage (sICH) was defined as neu-
rological deterioration of 4 or more points on the NIHSS and neu-
roimaging confirmed intracranial hemorrhage. The European co-
operative acute stroke study (ECASS I) was used to classify intra-
cranial hemorrhage [16]. Progression of ischemic stroke was 
defined as neurological deterioration with an increase of 2 or more 
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points on the NIHSS and follow-up cerebral imaging compatible 
with the diagnosis of ischemia (in the same territory) and no other 
underlying cause for neurological deterioration. 
Statistical Analysis
Baseline characteristics were described using standard statis-
tics. Patients for whom we could not obtain BMI were excluded 
from primary assessment. For univariate analysis with unimputed 
data, we used categorized BMI, and for multivariable analysis, we 
used BMI as a continuous variable. For the relation between BMI 
and functional outcome, we used multivariable ordinal logistic re-
gression analysis to estimate the adjusted common odds ratio for 
a shift in direction toward a better functional outcome on the mRS. 
Clinical and safety outcomes were adjusted for potential imbal-
ances in pre-specified prognostic variables adapted from the orig-
inal MR CLEAN trial protocol and from baseline differences: age, 
sex, NIHSS score at baseline, time from onset to randomization, 
hypertension, pre-stroke mRS score, and EVT. These variables 
were added to the model using a forward stepwise approach. For 
the interaction between BMI and EVT effect, we entered a multi-
plicative interaction term into the model. All descriptive analyses 
include patients with complete data, while all regression models 
include all the patients with imputed data. STATA (version 14.1) 
was used for all statistical analyses.
Results
Patient Characteristics
Out of 500 patients in the trial, 134 patients were ex-
cluded because of unrecorded height and/or weight leav-
ing 366 patients for this post hoc analysis. Because few 
patients were categorized as “underweight (n = 5)” or 
“morbidly obese (n = 15),” we decided to add them to 
the subgroups “normal weight” and “obesity,” respec-
tively. We report the comparison of patients with avail-
able BMI assessment vs. those without available BMI in 
online supplementary Table 1 (for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000504744; 
Online Recourse 1). The patients for whom BMI was un-
available more often had diabetes (19 vs. 11%) and had 
more risk of intracranial hemorrhage (11 vs. 5%). Base-
line characteristics of the remaining 366 patients are 
shown in Table 1. Of these, 160 patients (44%) were un-
derweight or normal weight, 145 patients (40%) were 
overweight, and 61 patients (17%) were obese or mor-
bidly obese. The presence of hypertension and the use of 
antiplatelet drugs were more common in the higher BMI 
class (p = 0.01). Slightly lesser number of patients were 
treated with EVT in the BMI< 25 groups (34%) com-
pared to the overweight and obese group (43%). In the 
EVT group, the duration of procedure and use of gen-
eral anesthesia were highest for obese patients though 
differences were not significant. 
BMI and Outcome 
The distribution of 90 day mRS scores is provided by 
trichotomized BMI subgroup and treatment allocation in 
Figure 1. In this univariate analysis, we noticed no par-
ticular shift on the mRS score between the BMI sub-
groups. However, for both treatment allocations, the 
mortality rate (mRS score 6) was proportionally lower in 
the higher BMI subgroups – respectively, 28, 19, 15% (p = 
0.36) for EVT-treated patients and 24, 24, 9% for patients 
treated without EVT (p = 0.13). 
In multivariable analysis with BMI as a continuous 
variable, there was a shift toward better functional out-
come (mRS at 90 days) with every point increase in 
BMI, adjusted common OR 1.04 (95% CI 1.00–0.09, p = 
0.048; Table 2). Secondary endpoint analysis showed 
that the risk of mortality declined when BMI increased 
(aOR 0.92, 95% CI 0.85–0.99, p = 0.02), and that higher 
BMI was associated with lower risk of stroke progres-
sion (aOR 0.92, 95% CI 0.87–0.99, p = 0.03). All other 
endpoint analyses showed no significant difference in 
BMI. 
BMI and EVT Treatment Effect 
We noted no interaction between BMI and EVT effect 
on mRS distribution, mortality, or stroke progression 
(adjusted p value for interaction = 0.85, 0.38, 0.61 respec-
tively). With regard to any of the other clinical or safety 
outcomes, there was also no treatment – BMI interaction. 
Discussion 
In this post hoc analysis of the MR CLEAN trial, we 
assessed the relation between BMI and outcome after 
EVT in acute stroke patients with LVO. The obesity par-
adox was found in terms of better functional outcome, 
lower mortality, and lower occurrence of stroke progres-
sion for patients with higher BMI. Additional analysis 
showed no interaction between BMI and EVT treatment 
effect. 
Our results are in line with previous studies reporting 
better 3-month recovery in overweight and obese stroke 
patients compared with normal weight counterparts [17–
19]. It should be noted that in the study of Kim et al. [19] 
the association between stroke outcome and BMI lost sta-
tistical significance after adjusting for initial stroke sever-
ity, which was not the case in our study. Because several 
studies in obesity report milder strokes and a higher prev-
alence of lacunar infarctions in obese patients, initial 
stroke severity was assumed to be a mediator between lev-
Obesity Paradox in Acute Ischemic Stroke 
Patients
203Cerebrovasc Dis 2019;48:200–206
DOI: 10.1159/000504744
Table 1. Baseline characteristics of patients with available BMI and p value for difference between BMI subgroups
Total (n = 366) BMI <25
(n = 160)
BMI 25–30
(n = 145)
BMI ≥30
(n = 61)
p value
Age, years, median (IQR) 64 (52–77) 67 (59–76) 66 (54–73) 0.11
Gender, male, n (%) 94 (59) 96 (66) 32 (52) 0.15
NIHSS score, median (IQR) 17 (14–22) 18 (14–21) 16 (14–21) 0.95
Clinical localization: left hemisphere n (%) 85 (53) 80 (55) 34 (56) 0.91
BMI, kg/m2, median (IQR) 23 (22–24) 27 (26–28) 33 (31–35) <0.01
Intravenous alteplase treatment, n (%) 145 (91) 129 (89) 55 (90) 0.88
Onset to randomization in min, median (IQR)* 200 (149–248) 203 (152–264) 178 (145–238) 0.22
Medical history, n (%)
Atrial fibrillation 37 (23) 37 (26) 22 (36) 0.14
Hypertension 57 (36) 75 (52) 31 (51) 0.01
Myocardial infarction 21 (13) 23 (16) 10 (16) 0.74
Hypercholesterolemia 33 (21) 39 (27) 19 (31) 0.21
Diabetes mellitus 18 (11) 15 (10) 9 (15) 0.66
Previous ischemic stroke 14 (9) 20 (14) 8 (13) 0.35
Peripheral artery disease 8 (5) 10 (7) 1 (2) 0.30
Pre-stroke mRs score 0.22
0 129 (81) 114 (79) 49 (80)
1 20 (13) 17 (12) 2 (3)
2 6 (4) 6 (4) 5 (8)
>2 5 (3) 8 (6) 5 (8)
Intoxication and medication, n (%)
Current smoking 53 (33) 41 (28) 18 (30) 0.64
Statin use 39 (24) 48 (33) 19 (31) 0.23
Antiplatelet use 34 (21) 51 (35) 20 (33) 0.02
Antihypertensive medication use 60 (38) 78 (54) 34 (56) 0.01
Imaging
ASPECTS on NCCT, median (IQR)* 9 (8–10) 9 (8–10) 9 (8–10) 0.93
Level of occlusion on non-invasive vessel imaging, n (%)* 0.78
ICA 2 (1) 1 (1) 1 (2)
ICA-T 49 (31) 35 (24) 15 (25)
M1 100 (63) 96 (67) 42 (69)
M2 9 (6) 12 (5) 3 (5)
Collateral score on CTA, n (%)† 0.42
0 9 (6) 7 (5) 0 
1 44 (28) 41 (28) 24 (39)
2 64 (40) 59 (41) 21 (34)
3 42 (26) 37 (26) 16 (26)
Procedure 
EVT treatment, n (%) 54 (34) 63 (43) 26 (43) 0.18
Duration of procedure in min
(of the EVT-treated patients), median (IQR) 81 (64–102) 68 (52–91) 83 (55–101) 0.18
Use of general anesthesia
(of the EVT-treated patients), n (%) 18 (33) 21 (33) 11 (42) 0.69* (n = 365), missing in 1 patient.† (n = 364), missing in 2 patients because CTA was not performed or images were of insufficient quality.
BMI, body mass index; CTA, computed tomographic angiography; EVT, endovascular treatment; ICA, intracranial artery; IQR, in-
terquartile range; NCCT, non-contrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin 
Scale. 
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els of BMI and post-stroke outcome, contradicting the 
existence of obesity paradox [4, 20]. However, our study 
concerns a distinct patient population with LVO, which 
is reflected in less influence of NIHSS dispersion and ini-
tial stroke severity. 
Apart from better functional outcome, our study 
also reports an inverse relation between BMI and post-
stroke mortality. By comparison, Olsen et al. [2] dem-
onstrated that post-stroke mortality was lowest in over-
weight and obese patients. This inverse relation was 
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Fig. 1. mRS distribution by treatment allo-
cation per BMI subgroup. BMI, body mass 
index; mRs, modified Rankin Scale; EVT, 
endovascular treatment.
Table 2. BMI association with outcome and p value for treatment interaction
Outcome variable BMI
Unadjusted OR
(95% CI)
BMI
Adjusted OR 
(95% CI)
p value BMI-treatment 
interaction 
(p value)
Clinical
mRS score at 90 days 1.03 (0.98 to 1.07) 1.04 (1.00 to 1.09) 0.048 0.86
mRS score of 0–2 at 90 days 1.01 (0.96 to 1.06) 1.02 (0.96 to 1.08) 0.47 0.24
NIHSS score at 24 h*, β (95% CI) 0.02 (–0.17 to 0.21) 0.004 (–0.16 to 0.17) 0.96 0.49
Mortality by 90 days 0.94 (0.88 to 1.00) 0.92 (0.85 to 0.99) 0.02 0.38
Radiological
No intracranial occlusion on 24 h CTA† 0.98 (0.93 to 1.03) 0.98 (0.92 to 1.03) 0.39 0.70
Final infarct volume on NCCT‡, β (95% CI) 0.77 (–2.94 to 1.39) –1.10 ( to 3.14 to 0.94) 0.29 0.32
Safety outcomes
sICH 1.03 (0.94 to 1.13) 1.04 (0.93 to 1.16) 0.52 0.78
Progression of stroke 0.93 (0.87 to 0.99) 0.93 (0.87 to 0.99) 0.03 0.61
Pneumonia 0.98 (0.92 to 1.05) 0.99 (0.92 to 1.06) 0.74 0.20† (n = 298), missing in 68 patients: imputed dataset.‡ (n = 240), missing in 126 patients: imputed dataset.* n = 358, missing in 8 patients: imputed dataset.
β, regression coefficient, estimated with linear regression analyses. 
OR for BMI association with outcome variable, estimated with logistic regression analyses. Adjustments were made for age, gender, 
NIHSS score at baseline, time from onset to randomization, hypertension, pre-mRS score, and EVT. 
BMI, body mass index; CTA, computed tomographic angiography; IQR, interquartile range; mRS, modified Rankin Scale; NCCT, 
non to contrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.
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also found in successive studies, though most of them 
reported on long-term mortality (1–2 years) [4, 21]. 
Long-term mortality is more likely to be influenced by 
comorbidity other than stroke and acute treatment. 
Therefore, we restricted our analyses to short-term 
mortality (within 90 days) in order to limit the risk of 
confounding. Furthermore, most studies also show 
higher mortality rates in underweight patients [2, 3, 
22]. Our study, however, had only 5 patients who were 
underweight (1.4% of study population), which may 
have influenced the effect on outcome by limited BMI 
dispersion. 
Post-stroke recovery is likely to be influenced by 
weight loss and muscle tissue degradation. Excess body 
weight may therefore have a protective effect by provid-
ing patients with metabolic reserves. From a biological 
point of view, the obesity paradox could be explained by 
potential protective effects of adipose tissue, as it blocks 
the release of inflammatory cytokines during catabolic 
state [23]. We consider this as a possible explanation for 
lower occurrence of stroke progression in our study. 
However, the exact underlying mechanism is still un-
clear, and we cannot exclude potential treatment bias as 
another cause of the obesity paradox, as it is possible that 
physicians and paramedics treat obese patients more ag-
gressively due to assumed increased risk of recurrent 
events. 
The strength of our study is the randomized trial de-
sign that enabled us to evaluate the impact of BMI on 
treatment effect. We note that the advantage of random-
ization does not apply in our comparison between BMI 
subgroups. Furthermore, all outcome measures have 
been collected prospectively according to protocol and 
irrespective of our present research question. 
Nevertheless, there are several limitations. First, the 
reported weight and height often resulted from estima-
tion, especially in an emergency setting. It is therefore 
possible that BMI measures were not obtained in a uni-
form way. Also, the diagnostic performance of BMI di-
minishes by increasing age, and alternative tools such as 
waist-to-hip ratio or waist circumference are proven to be 
more precise in the measurement of obesity [24, 25]. 
However, in clinical practice, BMI measurement is still 
the most pragmatic option. 
Second, we note that in our study, the association be-
tween BMI and functional outcome is most likely influ-
enced by the strong association between BMI and mortal-
ity since mortality is embedded in the mRS score. 
Third limitation concerns our post hoc design with 
the risk of inclusion bias. In our study, a rather large 
proportion of patients were excluded from analysis be-
cause of missing BMI. Additional analyses (online sup-
pl. Table 1) showed no difference in mortality rate be-
tween the included and excluded cohorts, though we 
did find a significant difference in the occurrence of 
sICH. Patient with missing BMI had higher occurrence 
of sICH compared to patients with no missing BMI. 
Consequently, selection bias could have affected our 
secondary outcome analysis while it likely has no effect 
on the primary and other secondary outcome mea-
sures.
In summary, in this post hoc analysis of a large ran-
domized controlled trial, we found a positive effect of in-
creased BMI on functional outcome and mortality in 
acute ischemic stroke patients with LVO, confirming the 
obesity paradox. Safety analysis also showed a lower risk 
of stroke progression in patients with higher BMI. How-
ever, there was no interaction between BMI and EVT ef-
fect, which means all the BMI classes may expect the same 
benefit from EVT.
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